D-penicillamine use is a recognised cause of drug-induced myopathy. The clinical objective is complete withdrawal of muscle symptoms through a structured pharmacological approach.
Among the notable side effects of D-penicillamine is the risk of developing an inflammatory myopathy resembling polymyositis or dermatomyositis. Identifying this drug-induced aetiology is a key step before defining the management strategy.
Management involves a corticosteroid-based strategy. The treatment goal is full withdrawal of muscle symptoms. The complete structured regimen — including decision criteria and sequencing — is accessible via the link below.
DOI: 10.3390/biomedicines12050987
The limitation of its usage is due, among other things, to the reported side effects, the notable ones being the risk of developing an inflammatory myopathy resembling polymyositis or dermatomyositis.
Most symptoms withdraw after treatment with corticosteroids.
View source ↗